Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
2.160
-0.170 (-7.30%)
At close: Jan 30, 2026, 4:00 PM EST
2.150
-0.010 (-0.46%)
After-hours: Jan 30, 2026, 7:24 PM EST
Coherus Oncology Stock Forecast
Stock Price Forecast
The 4 analysts that cover Coherus Oncology stock have a consensus rating of "Strong Buy" and an average price target of $5.51, which forecasts a 155.09% increase in the stock price over the next year. The lowest target is $1.05 and the highest is $10.
Price Target: $5.51 (+155.09%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coherus Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +362.96% | Jan 22, 2026 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +85.19% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +224.07% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | -51.39% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +224.07% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
44.29M
from 266.96M
Decreased by -83.41%
Revenue Next Year
79.58M
from 44.29M
Increased by 79.66%
EPS This Year
-1.47
from 0.25
EPS Next Year
-0.98
from -1.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.3M | 102.1M | ||||
| Avg | 44.3M | 79.6M | ||||
| Low | 41.2M | 60.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -81.5% | 130.5% | ||||
| Avg | -83.4% | 79.7% | ||||
| Low | -84.6% | 37.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.40 | -0.53 | ||||
| Avg | -1.47 | -0.98 | ||||
| Low | -1.50 | -1.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.